STELLA PHARMA CORPORATION has recently filed for approval to manufacture and sell a boron agent for BNCT

STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City; President: Tomoyuki Asano) has recently filed for approval to manufacture and sell a boron agent for boron neutron capture therapy (BNCT) (Code No.: SPM-011; generic name: borofalan [10B]; hereinafter referred to as the “drug”).